Mobile CME Courses

CMEinfo Insider is developed for medical professionals who want to save time & money. Get a $3,200 Amazon® gift card or save up to $3,200 when you join today!

Stay current on cutting edge content in your primary specialty, with a limitless opportunity to research topics important to you and your patients, earn unlimited AMA PRA Category 1 Credits,™ and take advantage of exceptional CME gift card opportunities.

A World of Medical Information at Your Fingertips

We partner with premier medical teaching institutions, professional associations, and highly regarded clinicians to deliver top-notch CME activities. They bring you the most relevant medical information for you to review and apply in your own practice.Connect to CMEinfo Insider and get:

• Comprehensive one-stop online resource for all stages of your medical career
• 24/7 access to the entire Insider library of board reviews, clinical updates, and journal article summaries from your computer, tablet or mobile device
• Earn all the AMA PRA Category 1 Credits™ you need
• Over 18,000 journal article summaries with audio commentary
• Over 1,230 board review and clinical update activities offered in video format
• New, cutting-edge topics added every month at no additional charge
• Online quizzes and instant pass/fail notification
• Unbiased and evidence-based content with no external advertising
• Pass board certification and maintenance of certification exams — guaranteed!
• Plus, save up to $3,200 or get up to a $3,200 Amazon® gift card when you join today! Please note that your receipt will be itemized per guidelines set forth by the ACCME for any accredited CME purchase sold in combination with a gift card. The gift card value is not a tax deductible professional expense. (See Gift Card Disclosures section below for further details.)

Notable disparities are present both with regard to individuals in the healthcare profession as well as in the delivery of healthcare to the patient population. Increasing awareness of the importance of diversity, equity, and inclusion is important for expanding access to high quality healthcare.

This presentation will be designed to introduce the audience to an important national level dialogue on the concepts of diversity, equity, and inclusion. Additionally, this topic will be tailored to understanding how DEI relates to healthcare practice and note specific steps the profession is taking to improve DEI at an organizational level.

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior. This activity discusses how to reduce the risk of ADHD with PTBM and drugs approved by the FDA for treatment of ADHD.

Every 7 minutes in our country, a person dies from a drug overdose, while a child is also born approximately every 30 minutes dependent on opioids. How do we as healthcare professionals offer non-stigmatic patient care and contribute to the progress of society in the right direction? Substance use disorder (addiction) is likened to an iceberg or a weed, in that the issues underneath the surface are typically even more complicated than what is viewed from the surface. Addiction spans hundreds of substances of abuse highlighted by stimulants (cocaine and methamphetamine), cannabis (plant, synthetics, and extracts), and opioids (heroin, fentanyl, and carfentanyl). As one can recall with the substance of ethyl alcohol (i.e. beer, wine, and hard liquor), a substance may never actually chemically change, yet can move across legal classifications of substances, leaving all healthcare professionals in need of knowledge on all substances of abuse. Opioid use disorder (opioid addiction) is combated with the medication-assisted treatments (MAT) of naltrexone, methadone, and buprenorphine, while opioid overdose respiratory depression is reversed with naloxone. Over the course of this activity, we will aim for “higher” education on all of these dynamic aspects. Unlike opioids, this activity is sure to open your eyes and possibly even elevate your blood pressure and/or heart rate!!!

With eight categories of HIV meds now available, healthcare professionals need to be up to date about these therapies. Whether using regimens from 20 years ago, or the newest drugs healthcare professionals need to be monitoring adherence to those regimens. By providing data from the San Francisco Study to show the needs for 95% adherence. This Florida-approved course will also describe the advantages and disadvantages of each category of drugs, as well as those individual drugs.

This course fulfills the ACCME, Florida Board of Medicine, and Florida Physician Assistants requirement to provide medical professionals with a clearer understanding of medical errors, the devastating effects that these errors can have on both patients and health care providers, and how to use root cause analysis to identify and prevent common medical errors.

This course fulfills the Florida Board requirement for MDs and PAs for a domestic violence training that discusses the categories, signs and symptoms, and reporting obligations for known or suspected domestic violence cases.

This course is designed for healthcare professionals and those in allied professions who may come into contact with and be called upon to intervene on behalf of victims of human trafficking within the scope of their practice.

According to the 2015 National Survey on Drug Use and Health, approximately 3.8 million people (1.4% of those ages 12 or older) reported misusing prescription pain relievers, while another 329,000 people reported using heroin. Within the same year, 52,404 lethal overdoses took place, making drug overdose the leading cause of accidental death within the United States. Stancliff et al estimated that as of 2012, approximately 80% of people dependent on heroin or prescription opioids were not engaged in any treatment and many in treatment do not use the most effective medication-assisted treatments available to them.

Despite recent increased awareness of opioid use disorder (OUD) and efforts to improve access to care, several barriers to treatment still exist, including financial, geographic, regulatory, and social. In 2012, only 2.2% of physicians in the United States obtained waivers to prescribe buprenorphine for the treatment of OUD. Of those who received waivers, 41.6% were psychiatrists. This may be perceived as a potential barrier to OUD treatment as patients are often resistant to referrals to psychiatric and/or addiction clinics given the stigmas commonly surrounding addiction and mental health. Furthermore, physicians with waivers were found to practice primarily in urban settings, leaving a large portion of the rural population without access to buprenorphine treatment.

With all this in mind, education is needed in regards to current and emerging treatment options for OUD available to multiple patient populations. Also, with the deaths due to drug overdoses still elevated, education on how to recognize and reverse an opioid overdose is needed.

This presentation will address the above needs by discussing the science behind opioid use disorder as well as reflect upon current statistics associated with its impact on the United States. During the discussion, opioid overdose risks will be discussed and participants will be able to practice recognizing key symptoms of an overdose situation. Steps of using naloxone will be discussed and connected to how to appropriately seek out treatment for maintenance of opioid use disorder. Finally, new buprenorphine products and the potential role of naltrexone will be applied to this stigmatized population.

This course provides 2 AMA PRA Category 1 Credit for license renewal and talks about the pharmacology, adverse effects, dosage, and administration of FDA-approved treatments for acute pain like nonopioid analgesics, adjuvant pain medications, migraine medicines, Tramadol/Celecoxib (Seglentis), Bupivacaine/Meloxicam (Zynrelef), IV Meloxicam (Anjeso), and Benzhydrocodone/Acetaminophen (Apadaz).